Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma.
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 12 Sep 2017 Results (n=333) of EORTC62043 and EORTC62072 trials assessing evolution in neutrophil to lymphocyte ratio in patients with advanced soft tissue sarcoma, presented at the 42nd European Society for Medical Oncology Congress.
- 12 Sep 2017 Results of a pooled analysis from EORTC 62012,EORTC62043 EORTC 62072 and EORTC62091 trials presented at the 42nd European Society for Medical Oncology Congress
- 11 Oct 2016 Results of a retrospective analysis from EORTC6204, EORTC62072 studies and additional clinical data from real life setting investigating the activity of pazopanib in vascular sarcomas, presented at the 41st European Society for Medical Oncology Congress